Barrett’s oesophagus is most strongly associated with the presence of GORD as a risk factor.

Understanding Barrett’s Oesophagus

Barrett’s oesophagus is a condition where the lower oesophageal mucosa is replaced by columnar epithelium, increasing the risk of oesophageal adenocarcinoma by 50-100 fold. It is typically identified during an endoscopy for upper gastrointestinal symptoms such as dyspepsia. The length of the affected segment correlates strongly with the chances of identifying metaplasia, with the overall prevalence estimated to be around 1 in 20. Risk factors include gastro-oesophageal reflux disease (GORD), male gender, smoking, and central obesity. Interestingly, alcohol does not seem to be an independent risk factor for Barrett’s. Management includes high-dose proton pump inhibitors and endoscopic surveillance with biopsies every 3-5 years for patients with metaplasia. If dysplasia of any grade is identified, endoscopic intervention such as radiofrequency ablation or endoscopic mucosal resection is offered.

Barrett’s oesophagus is a condition where the lower oesophageal mucosa is replaced by columnar epithelium, increasing the risk of oesophageal adenocarcinoma. It is typically identified during an endoscopy for upper gastrointestinal symptoms such as dyspepsia. The length of the affected segment correlates strongly with the chances of identifying metaplasia, with the overall prevalence estimated to be around 1 in 20. Risk factors include GORD, male gender, smoking, and central obesity. Interestingly, alcohol does not seem to be an independent risk factor for Barrett’s. Management includes high-dose proton pump inhibitors and endoscopic surveillance with biopsies every 3-5 years for patients with metaplasia. If dysplasia of any grade is identified, endoscopic intervention such as radiofrequency ablation or endoscopic mucosal resection is offered.

Patients with ‘unprovoked’ pulmonary embolisms usually require anticoagulation treatment for a duration of 6 months, as there are no temporary risk factors for venous thromboembolism.

Management of Pulmonary Embolism: NICE Guidelines

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management, and the guidelines recommend using apixaban or rivaroxaban as the first-line treatment following the diagnosis of a PE. If neither of these is suitable, LMWH followed by dabigatran or edoxaban or LMWH followed by a vitamin K antagonist (VKA) can be used. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation is determined by whether the VTE was provoked or unprovoked, with treatment typically stopped after 3-6 months for provoked VTE and continued for up to 6 months for unprovoked VTE.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak.

Overall, the updated NICE guidelines provide clear recommendations for the management of PE, including the use of DOACs as first-line treatment and outpatient management for low-risk patients. The guidelines also emphasize the importance of individualized treatment based on risk stratification and balancing the risks of VTE recurrence and bleeding.

Cystic fibrosis (CF) is a genetic condition that requires two copies of a faulty CFTR gene, one from each parent. If symptoms are present, it is important to confirm the diagnosis in the father and determine if the mother is a carrier of the faulty gene before pursuing further testing. While a sweat test can diagnose CF in the father, it cannot determine carrier status in the mother. Invasive procedures such as amniocentesis and chorionic villous sampling should only be performed if there is strong suspicion of a chromosomal or genetic abnormality, and less invasive genetic testing of both parents should be considered first. Karyotyping is not a useful diagnostic tool for CF, as it only detects chromosomal abnormalities and not genetic ones.

Medications and their potential to cause thrombocytopenia

Thrombocytopenia is a condition where there is a low platelet count in the blood, which can lead to bleeding and bruising. Some medications have been known to cause immune-mediated, drug-induced thrombocytopenia. Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), is one such medication. It interacts with platelet membrane glycoprotein, resulting in the formation of drug-glycoprotein complexes that can trigger the production of antibodies. The mechanism behind this is not entirely clear. Paracetamol and bisoprolol have a low likelihood of causing thrombocytopenia, making them safer alternatives. Simvastatin also has a low risk of causing thrombocytopenia. Warfarin, on the other hand, has a potential side effect of bleeding but is not directly linked to causing thrombocytopenia. It is important to be aware of the potential risks associated with medications and to consult with a healthcare professional before taking any new medication.

The traditional presentation of vestibular schwannoma involves a blend of symptoms such as vertigo, hearing impairment, tinnitus, and a missing corneal reflex.

An acoustic neuroma is typically linked to one-sided tinnitus and hearing loss.

Tinnitus and deafness are not commonly associated with multiple sclerosis (MS), which is a condition characterized by demyelination.

Chronic otitis media is a persistent inflammation of the middle ear and mastoid cavity, which is marked by recurring otorrhoea and conductive hearing loss.

Understanding Vestibular Schwannoma (Acoustic Neuroma)

Vestibular schwannoma, also known as acoustic neuroma, is a type of brain tumor that accounts for 5% of intracranial tumors and 90% of cerebellopontine angle tumors. The condition is characterized by a combination of symptoms such as vertigo, hearing loss, tinnitus, and an absent corneal reflex. The affected cranial nerves can predict the features of the condition. For instance, cranial nerve VIII can cause vertigo, unilateral sensorineural hearing loss, and unilateral tinnitus. On the other hand, cranial nerve V can lead to an absent corneal reflex, while cranial nerve VII can cause facial palsy.

Bilateral vestibular schwannomas are often seen in neurofibromatosis type 2. The diagnosis of vestibular schwannoma is made through an MRI of the cerebellopontine angle, and audiometry is also important since only 5% of patients have a normal audiogram.

The management of vestibular schwannoma involves surgery, radiotherapy, or observation. The choice of treatment depends on the size and location of the tumor, the patient’s age and overall health, and the severity of symptoms. In conclusion, understanding vestibular schwannoma is crucial in managing the condition effectively.

Treatment options for Cluster Headaches

Cluster headaches are a type of headache that is more common in men and presents with intense pain localized around one eye, accompanied by lacrimation and nasal congestion. The pain can last for a few minutes up to three hours and occurs every day for a number of weeks, followed by a symptom-free period. Here are some treatment options for cluster headaches:

Intranasal Sumatriptan: People over the age of 18 with acute bouts of confirmed cluster headache may be given a subcutaneous or nasal triptan for acute attacks.

Verapamil: Verapamil may be prescribed as a preventative treatment for cluster headaches but is not used during an acute attack. It is usually only prescribed following a discussion with a neurologist or a GP with a special interest in headaches.

Carbamazepine: Carbamazepine is used in the treatment of trigeminal neuralgia, which presents with sudden attacks of severe, shooting unilateral facial pain that feels like an ‘electric shock’. However, for cluster headaches, it is not the first-line treatment.

Codeine: Patients with cluster headaches should not be offered paracetamol, non-steroidal anti-inflammatory drugs or opioids as acute treatment, as they are too slow to take effect.

Short-burst oxygen therapy (home oxygen): Short-burst oxygen therapy (12–15 l/min via a non-rebreathe mask) can be prescribed to reduce the length of an attack, unless it is contraindicated. However, home oxygen is contraindicated for smokers due to the risk of fire.

In conclusion, cluster headaches can be debilitating, but there are various treatment options available to manage the symptoms. It is important to consult with a healthcare professional to determine the best course of treatment for each individual.

In cases of IPF, the TLCO (gas transfer test) is reduced, indicating a restrictive lung disease that results in a reduced FEV1 and reduced FVC. This leads to a normal or increased FEV1:FVC ratio, which is a distinguishing factor from obstructive lung diseases like COPD or asthma. Therefore, the correct statement is that in IPF, the FEV1:FVC ratio is normal or increased, while the TLCO is reduced.

Understanding Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition that causes progressive fibrosis of the interstitium of the lungs. Unlike other causes of lung fibrosis, IPF has no underlying cause. It is typically seen in patients aged 50-70 years and is more common in men.

The symptoms of IPF include progressive exertional dyspnoea, dry cough, clubbing, and bibasal fine end-inspiratory crepitations on auscultation. Diagnosis is made through spirometry, impaired gas exchange tests, and imaging such as chest x-rays and high-resolution CT scans.

Management of IPF includes pulmonary rehabilitation, but very few medications have been shown to be effective. Some evidence suggests that pirfenidone, an antifibrotic agent, may be useful in selected patients. Many patients will eventually require supplementary oxygen and a lung transplant.

The prognosis for IPF is poor, with an average life expectancy of around 3-4 years. CT scans can show advanced pulmonary fibrosis, including honeycombing. While there is no cure for IPF, early diagnosis and management can help improve quality of life and potentially prolong survival.

Understanding Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition that causes progressive fibrosis of the interstitium of the lungs. Unlike other causes of lung fibrosis, IPF has no underlying cause. It is typically seen in patients aged 50-70 years and is more common in men.

The symptoms of IPF include progressive exertional dyspnoea, dry cough, clubbing, and bibasal fine end-inspiratory crepitations on auscultation. Diagnosis is made through spirometry, impaired gas exchange tests, and imaging such as chest x-rays and high-resolution CT scans.

Management of IPF includes pulmonary rehabilitation, but very few medications have been shown to be effective. Some evidence suggests that pirfenidone, an antifibrotic agent, may be useful in selected patients. Many patients will eventually require supplementary oxygen and a lung transplant.

The prognosis for IPF is poor, with an average life expectancy of around 3-4 years. CT scans can show advanced pulmonary fibrosis, including honeycombing. While there is no cure for IPF, early diagnosis and management can help improve quality of life and potentially prolong survival.

Tardive dyskinesia can be caused by antipsychotics.

Antipsychotics are a group of drugs used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. They are associated with extrapyramidal side-effects and hyperprolactinaemia, which are less common with atypical antipsychotics.

Extrapyramidal side-effects (EPSEs) are common with typical antipsychotics and include Parkinsonism, acute dystonia, sustained muscle contraction, akathisia, and tardive dyskinesia. The latter is a late onset of choreoathetoid movements that may be irreversible and occur in 40% of patients. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients, including an increased risk of stroke and venous thromboembolism. Other side-effects include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval.

When it comes to quickly calming down patients who are exhibiting disruptive behavior, oral lorazepam is typically the first choice. According to NICE guidelines, either intramuscular lorazepam or a combination of intramuscular haloperidol and intramuscular promethazine should be used for rapid tranquilization in patients with acute behavioral disturbances. However, lorazepam is recommended for patients who have not previously taken antipsychotic medication and for those whose heart health is uncertain.

Understanding Psychosis

Psychosis is a term used to describe a person’s experience of perceiving things differently from those around them. This can manifest in various ways, including hallucinations, delusions, thought disorganization, alogia, tangentiality, clanging, and word salad. Associated features may include agitation/aggression, neurocognitive impairment, depression, and thoughts of self-harm. Psychotic symptoms can occur in a range of conditions, such as schizophrenia, depression, bipolar disorder, puerperal psychosis, brief psychotic disorder, neurological conditions, and drug use. The peak age of first-episode psychosis is around 15-30 years.

In a witnessed cardiac arrest with VF/VT rhythm, up to three quick successive shocks should be given before starting chest compressions. This is regarded as the first shock in the ALS algorithm. Adrenaline should be given every 3-5 minutes and a praecordial thump should only be used if a defibrillator is not available. Commencing CPR after just one shock would miss the opportunity to deliver three rapid shocks.

The 2015 Resus Council guidelines for adult advanced life support outline the steps to be taken when dealing with patients with shockable and non-shockable rhythms. For both types of patients, chest compressions are a crucial part of the process, with a ratio of 30 compressions to 2 ventilations. Defibrillation is recommended for shockable rhythms, with a single shock for VF/pulseless VT followed by 2 minutes of CPR. Adrenaline and amiodarone are the drugs of choice for non-shockable rhythms, with adrenaline given as soon as possible and amiodarone administered after 3 shocks for VF/pulseless VT. Thrombolytic drugs should be considered if a pulmonary embolus is suspected. Atropine is no longer recommended for routine use in asystole or PEA. Oxygen should be titrated to achieve saturations of 94-98% following successful resuscitation. The Hs and Ts should be considered as potential reversible causes of cardiac arrest.

The recommended first-line antibiotic for patients with confirmed Clostridium difficile infection is oral vancomycin. This infection typically occurs in patients who have recently taken broad-spectrum antibiotics, such as co-amoxiclav and ciprofloxacin, which disrupt the gut flora. Discontinuing the implicated antibiotic and starting appropriate eradicative therapy is necessary. Oral fidaxomicin is an alternative but is less available. Metronidazole is no longer a first-line antibiotic due to lower cure rates than vancomycin, but it may be used if vancomycin is not available. IV vancomycin is ineffective as insufficient quantities are excreted into the gut lumen. Clindamycin is not a cure for Clostridium difficile but is associated with an increased risk of developing it. Conservative management is not recommended as the infection may worsen and lead to complications such as toxic megacolon.

Clostridioides difficile is a type of bacteria that is commonly found in hospitals. It is a Gram positive rod that produces an exotoxin which can cause damage to the intestines, leading to a condition called pseudomembranous colitis. This bacteria usually develops when the normal gut flora is suppressed by broad-spectrum antibiotics, with second and third generation cephalosporins being the leading cause of C. difficile. Other risk factors include proton pump inhibitors. Symptoms of C. difficile include diarrhea, abdominal pain, and a raised white blood cell count. The severity of the infection can be determined using the Public Health England severity scale, which ranges from mild to life-threatening.

To diagnose C. difficile, a stool sample is tested for the presence of C. difficile toxin (CDT). Treatment for a first episode of C. difficile infection typically involves oral vancomycin for 10 days, with fidaxomicin or a combination of oral vancomycin and IV metronidazole being used as second and third-line therapies. Recurrent infections occur in around 20% of patients, increasing to 50% after their second episode. In such cases, oral fidaxomicin is recommended within 12 weeks of symptom resolution, while oral vancomycin or fidaxomicin can be used after 12 weeks. For life-threatening C. difficile infections, oral vancomycin and IV metronidazole are used, and surgery may be considered with specialist advice. Other therapies, such as bezlotoxumab and fecal microbiota transplant, may also be considered for preventing recurrences in certain cases.

The Royal College of Physicians (RCP) and NICE have published guidelines on the diagnosis and management of patients following a stroke. The management of acute stroke includes maintaining normal levels of blood glucose, hydration, oxygen saturation, and temperature. Blood pressure should not be lowered in the acute phase unless there are complications. Aspirin should be given as soon as possible if a haemorrhagic stroke has been excluded. Anticoagulants should not be started until brain imaging has excluded haemorrhage. Thrombolysis with alteplase should only be given if administered within 4.5 hours of onset of stroke symptoms and haemorrhage has been definitively excluded. Mechanical thrombectomy is a new treatment option for patients with an acute ischaemic stroke. NICE recommends thrombectomy for people who have acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography or magnetic resonance angiography. Secondary prevention includes the use of clopidogrel and dipyridamole. Carotid artery endarterectomy should only be considered if carotid stenosis is greater than 70% according to ECST criteria or greater than 50% according to NASCET criteria.

The combined oral contraceptive pill is associated with a higher likelihood of developing breast and cervical cancer, but it can also provide protection against ovarian and endometrial cancer.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than 1 per 100 woman years. It does not interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to the combined oral contraceptive pill. One of the main issues is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side-effects such as headache, nausea, and breast tenderness may also be experienced.

It is important to weigh the pros and cons of the combined oral contraceptive pill before deciding if it is the right method of birth control for you. While some users report weight gain while taking the pill, a Cochrane review did not support a causal relationship. Overall, the combined oral contraceptive pill can be an effective and convenient method of birth control, but it is important to discuss any concerns or potential risks with a healthcare provider.

Hypotonia in neonates can be caused by Down’s syndrome, but it is not the only cause. Down’s syndrome does not typically present with hyperreflexia or hypertonia, and it is not associated with spina bifida. While hyporeflexia may occur in some cases of Down’s syndrome, it is not the most common neurological presentation.

Understanding Hypotonia: Causes and Symptoms

Hypotonia, also known as floppiness, is a condition that can be caused by central nervous system disorders or nerve and muscle problems. It is characterized by a decrease in muscle tone, resulting in a lack of resistance to passive movement. In some cases, an acutely ill child may exhibit hypotonia during examination, while in others, it may be associated with encephalopathy in the newborn period, which is most likely caused by hypoxic ischaemic encephalopathy.

Central causes of hypotonia include Down’s syndrome, Prader-Willi syndrome, hypothyroidism, and cerebral palsy, which may precede the development of spasticity. On the other hand, neurological and muscular problems such as spinal muscular atrophy, spina bifida, Guillain-Barre syndrome, myasthenia gravis, muscular dystrophy, and myotonic dystrophy can also cause hypotonia.

It is important to note that hypotonia can be a symptom of an underlying condition and should be evaluated by a healthcare professional. Early diagnosis and treatment can help manage the symptoms and improve the quality of life for those affected.

This child’s symptoms, including oliguria, peripheral edema, petechial bruising, and pallor, suggest the possibility of hemolytic uremic syndrome (HUS). HUS is often associated with diarrheal illnesses and is characterized by normocytic anemia, thrombocytopenia, and acute kidney injury. The most common cause of HUS is Shiga-toxin producing Escherichia coli, which can be contracted from undercooked meat, such as a chicken burger from a carnival. While Campylobacter jejuni is a common cause of acute diarrhea, it is not typically associated with HUS. Clostridium perfringens can cause acute diarrhea and vomiting but is not associated with HUS. Salmonella species can also cause diarrheal illnesses, but they are not a common cause of HUS. In this case, Escherichia coli is the most likely causative organism.

Understanding Haemolytic Uraemic Syndrome

Haemolytic uraemic syndrome (HUS) is a condition that primarily affects young children and is characterized by a triad of symptoms, including acute kidney injury, microangiopathic haemolytic anaemia, and thrombocytopenia. The majority of cases are secondary and caused by Shiga toxin-producing Escherichia coli (STEC) 0157:H7, also known as ‘verotoxigenic’ or ‘enterohaemorrhagic’. Other causes of HUS include pneumococcal infection, HIV, systemic lupus erythematosus, drugs, and cancer. Primary HUS, also known as ‘atypical’, is caused by complement dysregulation.

To diagnose HUS, doctors may perform a full blood count to check for microangiopathic hemolytic anaemia and thrombocytopenia. A fragmented blood film may also be done to look for schistocytes and helmet cells. Additionally, a stool culture may be performed to check for evidence of STEC infection, and PCR for Shiga toxins may be done.

Treatment for HUS is supportive and may include fluids, blood transfusion, and dialysis if required. Antibiotics are not recommended, despite the preceding diarrhoeal illness in many patients. Plasma exchange may be considered for severe cases of HUS not associated with diarrhoea, while eculizumab, a C5 inhibitor monoclonal antibody, has shown greater efficiency than plasma exchange alone in the treatment of adult atypical HUS.

Overall, understanding the causes, symptoms, and management of HUS is crucial for healthcare professionals to provide appropriate care for patients with this condition.

Should red eye be attributed to glaucoma or uveitis?
Glaucoma is characterized by intense pain, haloes, and a partially dilated pupil, while uveitis is indicated by a small, fixed oval pupil and ciliary flush.

Understanding the Causes of Red Eye

Red eye is a common condition that can be caused by various factors. It is important to identify the underlying cause of red eye to determine the appropriate treatment. In some cases, urgent referral to an ophthalmologist may be necessary. Here are some of the key distinguishing features of the different causes of red eye:

Acute angle closure glaucoma is characterized by severe pain, decreased visual acuity, and haloes. The pupil may also be semi-dilated and the cornea hazy.

Anterior uveitis presents with acute onset, pain, blurred vision, and photophobia. The pupil is small and fixed, and there may be ciliary flush.

Scleritis is characterized by severe pain and tenderness, which may worsen with movement. It may also be associated with underlying autoimmune diseases such as rheumatoid arthritis.

Conjunctivitis may be bacterial or viral, with purulent or clear discharge, respectively.

Subconjunctival haemorrhage may be caused by trauma or coughing bouts.

Endophthalmitis typically occurs after intraocular surgery and presents with red eye, pain, and visual loss.

By understanding the different causes of red eye and their distinguishing features, healthcare professionals can provide appropriate management and referral when necessary.

Chancroid is the culprit behind painful genital ulcers that have a ragged border and are accompanied by tender inguinal lymphadenopathy. Haemophilus ducreyi is the organism responsible for causing chancroid. While herpes simplex virus can also cause painful genital ulcers, they tend to be smaller and multiple, and primary attacks are often accompanied by fever. On the other hand, lymphogranuloma venereum is caused by C. trachomatis, syphilis by T. pallidum, and granuloma inguinale by K. granulomatis, all of which result in painless genital ulcers.

Understanding Chancroid: A Painful Tropical Disease

Chancroid is a disease that is commonly found in tropical regions and is caused by a bacterium called Haemophilus ducreyi. This disease is characterized by the development of painful genital ulcers that are often accompanied by painful swelling of the lymph nodes in the groin area. The ulcers themselves are typically easy to identify, as they have a distinct border that is ragged and undermined.

Chancroid is a disease that can be quite painful and uncomfortable for those who are affected by it.

Understanding the Association between H. pylori Infection and Gastric Diseases

H. pylori infection is a common bacterial infection that affects approximately 50% of the global population. While it is primarily associated with peptic ulcer disease, it can also lead to other gastric diseases. Gastric malignancies, for instance, are often caused by chronic inflammation of MALT from H. pylori infection. MALTomas, which are extranodal marginal zone B-cell lymphomas, are the most common type of gastric lymphoma and are associated with H. pylori infection in over 90% of cases.

However, not all gastric diseases are associated with H. pylori infection. Coeliac disease, for example, is an autoimmune disorder related to gluten sensitivity. Non-ulcer dyspepsia, a group of upper gastrointestinal symptoms, is not generally associated with H. pylori infection. Reflux oesophagitis, a condition caused by the failure of relaxation of the lower end of the oesophagus, is also not associated with H. pylori infection.

It is important to note that the development of gastric malignancies from H. pylori infection is a slow process that may stop at any step. The disease process starts with chronic gastritis, followed by atrophic gastritis, intestinal metaplasia, dysplasia, and eventually gastric malignancy (Correa’s cascade). However, other factors are also required for gastric cancers to develop, not just H. pylori infection.

In conclusion, understanding the association between H. pylori infection and gastric diseases is crucial in the diagnosis and treatment of these conditions. While H. pylori infection is a common cause of gastric malignancies, it is not associated with all gastric diseases.

According to NICE 2017 guidelines, if a patient with asthma is not effectively managed with a SABA + ICS, the first step should be to add a LTRA rather than a LABA.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.